Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma.

PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Further Study Information

OBJECTIVES:

Primary

• To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) of patients with symptomatic or progressive low-grade gliomas.

• To determine whether the addition of temozolomide to fractionated radiotherapy improves the median overall survival (OS) of these patients.

Secondary

• To determine whether combination therapy with temozolomide and radiotherapy improves or maintains cognition and quality of life compared to radiotherapy alone.

• To compare the toxicities (severe or worse [≥ grade 3]) of radiotherapy with vs without temozolomide in these patients.

• To assess the impact of the presence or absence of 1p and 19q deletion on PFS and OS.

• To determine the impact of 1p and 19q status on PFS and OS of patients treated with temozolomide.

• To create a tumor and tissue bank, including plasma and germ line DNA, within the ECOG Pathology Coordinating Office.

OUTLINE: This is a multicenter study. Patients are stratified according to age (< 40 years vs ≥ 40 years), 1p and 19q status (both deleted vs either/both intact vs undeterminable), pre-operative maximum tumor diameter (< 6 cm vs ≥ 6 cm [based on T2 or FLAIR MRI]), Karnofsky performance status (60-70% vs 80-100%), and contrast enhancement on pre-treatment MRI scan (present vs absent). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).

• Arm II: Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Some patients undergo quality-of-life and neurocognitive (e.g., visual scanning speed, divided attention, language, memory, and fine motor skills) assessments at baseline, annually until disease progression, and at the time of disease progression.

Tumor tissue samples are collected at baseline for confirmation of diagnosis and determination of 1p and 19q deletion status. Peripheral blood, serum, and additional tumor tissue samples may be collected for further research studies.

After completion of study treatment, patients are followed up periodically for up to 15 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed* supratentorial low-grade glioma, including 1 of the following:

• Grade 2 astrocytoma

• Grade 2 oligodendroglioma

• Grade 2 oligoastrocytoma (mixed glioma containing astrocytoma and oligodendroglioma)

• NOTE: *If the pathology from multiple procedures supports the diagnosis of a brain tumor, the qualifying pathology of grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma must be the most recent pathological diagnosis; no pathological diagnosis of grade 3 or 4 glioma at any time

• Paraffin-embedded tumor specimen available for submission for confirmation of pathological review and determination of 1p and 19q deletion status

• Patients must currently meet ≥ 1 of the following criteria*:

• Uncontrolled symptoms, defined as any of the following:

• Headaches associated with mass effect

• Uncontrolled seizures despite two different antiepileptic drug regimens (i.e., two antiepileptic drugs tested either sequentially or in combination)

• Focal neurological symptoms

• Cognitive symptoms or deficits

• Tumor progression by serial MRIs, defined as any of the following:

• New or progressive enhancement

• New or progressive T2 or FLAIR signal abnormality

• Age ≥ 40 years

• NOTE: *Patients < 40 years of age whose only symptom of low-grade glioma is seizures that are well-controlled on antiepileptic drugs AND who have no evidence of radiographic progression are not eligible.

• Patients who have undergone gross total resection and have no detectable residual disease are eligible

• No pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%

• WBC ≥ 3,000/mm^3

• ANC ≥ 1,500/mm^3

• Platelet count ≥ 100,000/mm^3

• Hematocrit ≥ 30%

• Bilirubin ≤ 2 times upper limit of normal (ULN)

• AST and ALT ≤ 3 times ULN

• Creatinine ≤ 2.0 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Able to undergo MRI with and without contrast

• No other malignancy within the past 5 years, except for nonmelanoma skin cancer or cervical carcinoma in situ

• No uncontrolled infection

• No known HIV positivity

• No medical disorder that would increase risks associated with radiotherapy and temozolomide

• No other disorder that would limit life expectancy to < 5 years

PRIOR CONCURRENT THERAPY:

• No prior radiotherapy, cytotoxic chemotherapy, radiosurgery, or investigational therapy directed at the brain tumor

• Any number of prior surgical procedures for the brain tumor allowed

• No prior radiotherapy to the head unless the radiotherapy ports entirely excluded the brain

• At least 2 weeks since any prior brain surgery (e.g., stereotatic biopsy, open biopsy, or resection)

• At least 6 weeks since prior MRI and chest x-ray

• If resection is performed, an MRI after surgery is required

Trial Contact Information

Trial Lead Organizations/Sponsors

Eastern Cooperative Oncology Group

David Schiff

Study Chair

U.S.A.
Arizona
	Phoenix
	Arizona Oncology - Deer Valley Center
		David G. Brachman	Ph: 800-360-6371
	Arizona Oncology Services Foundation
		David G. Brachman	Ph: 800-360-6371
California
	LA Jolla
	Rebecca and John Moores UCSD Cancer Center
		Santosh Kesari	Ph: 858-822-5354
			Email: cancercto@ucsd.edu
	Orange
	Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
		Daniela A Bota	Ph: 877-827-8839
			Email: ucstudy@uci.edu
Colorado
	Aurora
	Medical Center of Aurora - South Campus
		Eduardo R. Pajon	Ph: 888-785-6789
	Denver
	CCOP - Colorado Cancer Research Program
		Eduardo R. Pajon	Ph: 888-785-6789
	Porter Adventist Hospital
		Eduardo R. Pajon	Ph: 888-785-6789
	Presbyterian - St. Luke's Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
	St. Anthony Central Hospital
		Eduardo R. Pajon	Ph: 888-785-6789
	St. Joseph Hospital
		Eduardo R. Pajon	Ph: 888-785-6789
	Englewood
	Swedish Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
	Lone Tree
	Sky Ridge Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
Connecticut
	Norwich
	Eastern Connecticut Hematology and Oncology Associates
		Dennis E. Slater	Ph: 860-886-8362
Delaware
	Newark
	Helen F. Graham Cancer Center at Christiana Hospital
		Gregory A. Masters	Ph: 302-733-6227
Florida
	Jacksonville
	Mayo Clinic - Jacksonville
		Nadia N Laack	Ph: 507-538-7623
	Orlando
	Florida Hospital Cancer Institute at Florida Hospital Orlando
		Lee M. Zehngebot	Ph: 407-303-5623
Illinois
	Bloomington
	St. Joseph Medical Center
		John W. Kugler	Ph: 800-793-2262
	Bloomington%
	Illinois CancerCare - Bloomington
		John W. Kugler	Ph: 800-793-2262
	Canton
	Illinois CancerCare - Canton
		John W. Kugler	Ph: 800-793-2262
	Carthage
	Illinois CancerCare - Carthage
		John W. Kugler	Ph: 800-793-2262
	Chicago
	John H. Stroger, Jr. Hospital of Cook County
		Thomas E. Lad	Ph: 312-864-6000
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		Jeffrey J. Raizer	Ph: 312-695-1301
			Email: cancer@northwestern.edu
	University of Illinois Cancer Center
		John L Villano	Ph: 859-257-3379
	Decatur
	Decatur Memorial Hospital Cancer Care Institute
		James L. Wade	Ph: 217-876-4740
			Email: kcheek@dmhhs.org
	Eureka
	Eureka Community Hospital
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Eureka
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Galesburg
	Galesburg Clinic, PC
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Havana
	Illinois CancerCare - Havana
		John W. Kugler	Ph: 800-793-2262
	Kewanee
	Illinois CancerCare - Kewanee Clinic
		John W. Kugler	Ph: 800-793-2262
	Macomb
	Illinois CancerCare - Macomb
		John W. Kugler	Ph: 800-793-2262
	Monmouth
	Illinois CancerCare - Monmouth
		John W. Kugler	Ph: 800-793-2262
	OSF Holy Family Medical Center
		John W. Kugler	Ph: 800-793-2262
	Normal
	BroMenn Regional Medical Center
		John W. Kugler	Ph: 800-793-2262
	Community Cancer Center
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Community Cancer Center
		John W. Kugler	Ph: 800-793-2262
	Ottawa
	Community Hospital of Ottawa
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Ottawa
		John W. Kugler	Ph: 800-793-2262
	Pekin
	Cancer Treatment Center at Pekin Hospital
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Illinois CancerCare - Pekin
		John W. Kugler	Ph: 800-793-2262
	Peoria
	CCOP - Illinois Oncology Research Association
		John W. Kugler	Ph: 800-793-2262
	Illinois CancerCare - Peoria
		John W. Kugler	Ph: 800-793-2262
	Methodist Medical Center of Illinois
		John W. Kugler	Ph: 800-793-2262
	OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	OSF St. Francis Medical Center
		John W. Kugler	Ph: 800-793-2262
	Proctor Hospital
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Peru
	Illinois CancerCare - Princeton
		John W. Kugler	Ph: 800-793-2262
	Illinois Valley Community Hospital
		John W. Kugler	Ph: 800-793-2262
	Princeton
	Illinois CancerCare - Princeton
		John W. Kugler	Ph: 800-793-2262
	Spring Valley
	Illinois CancerCare - Spring Valley
		John W. Kugler	Ph: 800-793-2262
	Valley Cancer Center
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
Indiana
	Elkhart
	Elkhart General Hospital
		Bilal Ansari	Ph: 574-237-1328
	Fort Wayne
	Parkview Regional Cancer Center at Parkview Health
		Brian K Chang	Ph: 260-373-8888
			Email: parkviewresearch@parkview.com
	Radiation Oncology Associates Southwest
		Brian K Chang	Ph: 260-373-8888
			Email: parkviewresearch@parkview.com
	Indianapolis
	Community Regional Cancer Care at Community Hospital East
		Shih J Wei	Ph: 800-777-7775
	Community Regional Cancer Care at Community Hospital North
		Shih J Wei	Ph: 800-777-7775
	Kokomo
	Community Cancer Care at Howard Regional Health System
		Bilal Ansari	Ph: 574-237-1328
	La Porte
	Center for Cancer Therapy at LaPorte Hospital and Health Services
		Bilal Ansari	Ph: 574-237-1328
	South Bend
	CCOP - Northern Indiana CR Consortium
		Bilal Ansari	Ph: 574-237-1328
	Memorial Hospital of South Bend
		Bilal Ansari	Ph: 574-237-1328
Iowa
	Des Moines
	CCOP - Iowa Oncology Research Association
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Mason City
	Mercy Cancer Center at Mercy Medical Center - North Iowa
		Arvind Y Vemula	Ph: 800-433-3883
	Sioux City
	Siouxland Hematology-Oncology Associates, LLP
		Donald Bruce Wender	Ph: 712-252-0088
Kansas
	Chanute
	Cancer Center of Kansas, PA - Chanute
		Shaker R. Dakhil	Ph: 316-262-4467
	Dodge City
	Cancer Center of Kansas, PA - Dodge City
		Shaker R. Dakhil	Ph: 316-262-4467
	El Dorado
	Cancer Center of Kansas, PA - El Dorado
		Shaker R. Dakhil	Ph: 316-262-4467
	Kingman
	Cancer Center of Kansas, PA - Kingman
		Shaker R. Dakhil	Ph: 316-262-4467
	Lawrence
	Lawrence Memorial Hospital
		Shaker R. Dakhil	Ph: 316-262-4467
	Newton
	Cancer Center of Kansas, PA - Newton
		Shaker R. Dakhil	Ph: 316-262-4467
	Parsons
	Cancer Center of Kansas, PA - Parsons
		Shaker R. Dakhil	Ph: 316-262-4467
	Pratt
	Cancer Center of Kansas, PA - Pratt
		Shaker R. Dakhil	Ph: 316-262-4467
	Salina
	Cancer Center of Kansas, PA - Salina
		Shaker R. Dakhil	Ph: 316-262-4467
	Wellington
	Cancer Center of Kansas, PA - Wellington
		Shaker R. Dakhil	Ph: 316-262-4467
	Wichita
	Associates in Women's Health, PA - North Hillside
		Shaker R. Dakhil	Ph: 316-262-4467
	Cancer Center of Kansas, PA - Medical Arts Tower
		Shaker R. Dakhil	Ph: 316-262-4467
	Cancer Center of Kansas, PA - Wichita
		Shaker R. Dakhil	Ph: 316-262-4467
	CCOP - Wichita
		Shaker R. Dakhil	Ph: 316-262-4467
	Via Christi Cancer Center at Via Christi Regional Medical Center
		Shaker R. Dakhil	Ph: 316-262-4467
	Winfield
	Cancer Center of Kansas, PA - Winfield
		Shaker R. Dakhil	Ph: 316-262-4467
Maryland
	Baltimore
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
		Jaishri O'Neill Blakeley	Ph: 410-955-8804
			Email: jhcccro@jhmi.edu
	Elkton MD
	Union Hospital of Cecil County
		Gregory A. Masters	Ph: 302-733-6227
Michigan
	Detroit
	Josephine Ford Cancer Center at Henry Ford Hospital
		Robert Anthony Chapman	Ph: 313-916-1784
	Flint
	Hurley Medical Center
		Philip J. Stella	Ph: 734-712-3456
	Kalamazoo
	West Michigan Cancer Center
		Raymond Sterling Lord	Ph: 269-373-7458
	Saint Joseph
	Lakeside Cancer Specialists, PLLC
		Bilal Ansari	Ph: 574-237-1328
	St. Joseph
	Lakeland Regional Cancer Care Center - St. Joseph
		Bilal Ansari	Ph: 574-237-1328
Minnesota
	Burnsville
	Fairview Ridges Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Coon Rapids
	Mercy and Unity Cancer Center at Mercy Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Duluth
	CCOP - Duluth
		Bret E Friday	Ph: 888-203-7267
	Edina
	Fairview Southdale Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Fridley
	Mercy and Unity Cancer Center at Unity Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Hutchinson
	Hutchinson Area Health Care
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Maplewood
	HealthEast Cancer Care at St. John's Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Minnesota Oncology - Maplewood
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Minneapolis
	Hennepin County Medical Center - Minneapolis
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Robbinsdale
	Humphrey Cancer Center at North Memorial Outpatient Center
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Rochester
	Mayo Clinic Cancer Center
		Nadia N Laack	Ph: 507-538-7623
	Saint Louis Park
	CCOP - Metro-Minnesota
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Park Nicollet Cancer Center
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Saint Paul
	Regions Hospital Cancer Care Center
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	United Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Shakopee
	St. Francis Cancer Center at St. Francis Medical Center
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Stillwater
	Lakeview Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Waconia
	Ridgeview Medical Center
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Willmar
	Willmar Cancer Center at Rice Memorial Hospital
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Woodbury
	Minnesota Oncology - Woodbury
		Joseph W Leach	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
Montana
	Billings
	Billings Clinic Cancer Center - 801 N 29th Street
		Benjamin Thomas Marchello	Ph: 800-648-6274
Nebraska
	Lincoln
	Cancer Resource Center - Lincoln
		Gamini S. Soori	Ph: 800-253-4368
	Omaha
	CCOP - Missouri Valley Cancer Consortium
		Gamini S. Soori	Ph: 800-253-4368
	Methodist Estabrook Cancer Center
		Tien-Shew W Huang	Ph: 402-354-5144
	UNMC Eppley Cancer Center at the University of Nebraska Medical Center
		Weining K. Zhen	Ph: 402-559-8555
			Email: llarson@unmc.edu
New Hampshire
	Lebanon
	Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
		Camilo E. Fadul	Ph: 800-639-6918
			Email: cancer.research.nurse@dartmouth.edu
New York
	Albany
	New York Oncology Hematology, PC at Albany Medical Center
		Charles H Weissman	Ph: 518-489-3612ext1342
			Email: sharon.krause@usoncology.com
	New York
	Memorial Sloan-Kettering Cancer Center
		Thomas J Kaley	Ph: 212-639-7202
	Syracuse
	SUNY Upstate Medical University Hospital
		Thomas Edward Coyle	Ph: 315-464-5476
North Carolina
	Winston-Salem
	Wake Forest University Comprehensive Cancer Center
		Glenn J Lesser	Ph: 336-713-6771
Ohio
	Akron
	Summa Center for Cancer Care at Akron City Hospital
		Jennifer E Payne	Ph: 330-375-6101
	Barberton
	Barberton Citizens Hospital
		Jennifer E Payne	Ph: 330-375-6101
	Cincinnati
	University of Cincinnati
		Luke E Pater	Ph: 513-558-4553
			Email: uchealthnews@uc.edu
	Cleveland
	Case Comprehensive Cancer Center
		Charles J Nock	Ph: 800-641-2422
	Cleveland Clinic Taussig Cancer Center
		Samuel T Chao	Ph: 866-223-8100
	Columbus
	Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
		Robert Cavaliere	Ph: 866-627-7616
			Email: osu@emergingmed.com
Pennsylvania
	Allentown
	Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
		Eliot Lawrence Friedman	Ph: 610-402-2273
	Bethlehem
	St. Luke's Cancer Network at St. Luke's Hospital
		Sanjiv S. Agarwala	Ph: 610-954-3582
			Email: infolink@slhn.org
	Philadelphia
	Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
		Maria Werner-Wasik	Ph: 215-955-6084
South Carolina
	Charleston
	Hollings Cancer Center at Medical University of South Carolina
		Pierre Giglio	Ph: 843-792-9321
	Greenville
	Cancer Centers of the Carolinas - Andrews
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Faris Road
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Grove Commons
		David L Grisell	Ph: 864-241-6251
	CCOP - Greenville
		David L Grisell	Ph: 864-241-6251
	Greer
	Cancer Centers of the Carolinas - Greer Medical Oncology
		David L Grisell	Ph: 864-241-6251
	Cancer Centers of the Carolinas - Greer Radiation Oncology
		David L Grisell	Ph: 864-241-6251
	Seneca
	Cancer Centers of the Carolinas - Seneca
		David L Grisell	Ph: 864-241-6251
	Spartanburg
	Cancer Centers of the Carolinas - Spartanburg
		David L Grisell	Ph: 864-241-6251
	CCOP - Upstate Carolina
		Charles E Bowers	Ph: 800-486-5941
	Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
		Charles E Bowers	Ph: 800-486-5941
South Dakota
	Rapid City
	Rapid City Regional Hospital
		Richard C Tenglin	Ph: 605-716-3982
			Email: research@rcrh.org
	Sioux Falls
	Sanford Cancer Center at Sanford USD Medical Center
		Miroslaw A Mazurczak	Ph: 605-328-1367
Tennessee
	Nashville
	Vanderbilt-Ingram Cancer Center
		Paul L. Moots	Ph: 800-811-8480
Texas
	Dallas
	Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
		Kevin S Choe	Ph: 214-648-7097
	Houston
	Univeristy of Texas M.D. Anderson Cancer Center
		John F de Groot	Ph: 713-792-3245
Utah
	Murray
	Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
		Gordon A Watson	Ph: 801-507-3950
	Provo
	Utah Valley Regional Medical Center - Provo
		Gordon A Watson	Ph: 801-507-3950
	Saint George
	Dixie Regional Medical Center - East Campus
		Gordon A Watson	Ph: 801-507-3950
Virginia
	Richmond
	Virginia Commonwealth University Massey Cancer Center
		Douglas W Arthur	Ph: 804-628-1939
Washington
	Seattle
	CCOP - Virginia Mason Research Center
		Jacqueline Vuky	Ph: 503-299-6500
	University Cancer Center at University of Washington Medical Center
		George E. Laramore	Ph: 206-616-8289
Wisconsin
	Eau Claire
	Marshfield Clinic Cancer Care at Regional Cancer Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Green Bay
	St. Vincent Hospital Regional Cancer Center
		Gerald K. Bayer	Ph: 800-432-6049
	La Crosse
	Gundersen Lutheran Center for Cancer and Blood
		Kurt Oettel	Ph: 608-775-2385
			Email: cancerctr@gundluth.org
	Madison
	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
		H. Ian Robins	Ph: 877-405-6866
	Marshfield
	Marshfield Clinic - Marshfield Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Saint Joseph's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Mequon
	Columbia Saint Mary's Hospital - Ozaukee
		Carl E. Olson	Ph: 414-326-2675
			Email: clinicaltrials@columbia-stmarys.org
	Milwaukee
	Columbia-Saint Mary's Cancer Care Center
		Carl E. Olson	Ph: 414-326-2675
			Email: clinicaltrials@columbia-stmarys.org
	Froedtert Hospital and Medical College of Wisconsin
		Christopher J. Schultz	Ph: 414-805-4380
	Minocqua
	Marshfield Clinic - Lakeland Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Rhinelander
	Ministry Medical Group at Saint Mary's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Rice Lake
	Marshfield Clinic - Indianhead Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Stevens Point
	Marshfield Clinic at Saint Michael's Hospital
		Benjamin E. Lawler	Ph: 715-389-4457
	Waukesha
	Waukesha Memorial Hospital Regional Cancer Center
		Michael A Thompson	Ph: 262-928-7632
	Weston
	Diagnostic and Treatment Center
		Benjamin E. Lawler	Ph: 715-389-4457
	Marshfield Clinic - Weston Center
		Benjamin E. Lawler	Ph: 715-389-4457

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00978458
Information obtained from ClinicalTrials.gov on December 05, 2012

Back to Top